Cargando…

OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants

Disclosure: V. Aslanzadeh: None. G. Brierley: None. G. Kudla: None. R.K. Semple: None. Loss-of-function mutations in the gene for the human insulin receptor, INSR, cause either autosomal dominant or autosomal recessive severe insulin resistance. Biallelic mutations produce extreme insulin resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslanzadeh, Vahid, Brierley, Gemma, Kudla, Grzegorz, Kenneth Semple, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555934/
http://dx.doi.org/10.1210/jendso/bvad114.893
_version_ 1785116768839139328
author Aslanzadeh, Vahid
Brierley, Gemma
Kudla, Grzegorz
Kenneth Semple, Robert
author_facet Aslanzadeh, Vahid
Brierley, Gemma
Kudla, Grzegorz
Kenneth Semple, Robert
author_sort Aslanzadeh, Vahid
collection PubMed
description Disclosure: V. Aslanzadeh: None. G. Brierley: None. G. Kudla: None. R.K. Semple: None. Loss-of-function mutations in the gene for the human insulin receptor, INSR, cause either autosomal dominant or autosomal recessive severe insulin resistance. Biallelic mutations produce extreme insulin resistance which is commonly fatal in infancy or childhood. A wide and growing number of mutations have been associated with disease, with few recurring mutations, and only a small subset have been studied functionally to date. Discriminating loss-of-function pathogenic alleles from insignificant variants is an important barrier to diagnosis and translational studies of novel candidate treatments. Such candidate therapies include a variety of antibody, peptide and small molecule ligands that activate the receptor in a manner distinct to insulin. These show potential to activate mutant receptors that are expressed but show impaired insulin binding or responsiveness. To address this barrier to translation we have now used massively multiplexed, Flow-Seq-based assays simultaneously to determine the effects of 14,000 human INSR extracellular domain missense variants. We assayed receptor cell surface expression, insulin binding and signal transduction using heterologous expression of mutants in mouse embryonic cells in which endogenous Insr and Igf1r genes had been knocked out or knocked down. Preliminary analysis reliably discriminates A. variants that reduce or abolish receptor cell surface expression when measured with two different monoclonal anti-receptor antibodies B. variants with preserved cell surface expression but selectively impaired binding of insulin and C. an overlapping group of variants with severely impaired signalling response to insulin but preserved response to antibody. Our assay confirmed previously studied attributes of a panel of disease-causing variants, and shows strong agreement with prior alanine scanning mutagenesis studies and structural predictions. We thus provide a rich sequence-function map for INSR variant interpretation. A prediction tool trained on known pathogenic INSR alleles is currently being developed for access by the community both to accelerate confident molecular diagnosis of newly identified rare INSR variants, and also to aid stratification of mutations according to potential for activation by non canonical INSR ligands. Presentation: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10555934
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105559342023-10-07 OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants Aslanzadeh, Vahid Brierley, Gemma Kudla, Grzegorz Kenneth Semple, Robert J Endocr Soc Diabetes And Glucose Metabolism Disclosure: V. Aslanzadeh: None. G. Brierley: None. G. Kudla: None. R.K. Semple: None. Loss-of-function mutations in the gene for the human insulin receptor, INSR, cause either autosomal dominant or autosomal recessive severe insulin resistance. Biallelic mutations produce extreme insulin resistance which is commonly fatal in infancy or childhood. A wide and growing number of mutations have been associated with disease, with few recurring mutations, and only a small subset have been studied functionally to date. Discriminating loss-of-function pathogenic alleles from insignificant variants is an important barrier to diagnosis and translational studies of novel candidate treatments. Such candidate therapies include a variety of antibody, peptide and small molecule ligands that activate the receptor in a manner distinct to insulin. These show potential to activate mutant receptors that are expressed but show impaired insulin binding or responsiveness. To address this barrier to translation we have now used massively multiplexed, Flow-Seq-based assays simultaneously to determine the effects of 14,000 human INSR extracellular domain missense variants. We assayed receptor cell surface expression, insulin binding and signal transduction using heterologous expression of mutants in mouse embryonic cells in which endogenous Insr and Igf1r genes had been knocked out or knocked down. Preliminary analysis reliably discriminates A. variants that reduce or abolish receptor cell surface expression when measured with two different monoclonal anti-receptor antibodies B. variants with preserved cell surface expression but selectively impaired binding of insulin and C. an overlapping group of variants with severely impaired signalling response to insulin but preserved response to antibody. Our assay confirmed previously studied attributes of a panel of disease-causing variants, and shows strong agreement with prior alanine scanning mutagenesis studies and structural predictions. We thus provide a rich sequence-function map for INSR variant interpretation. A prediction tool trained on known pathogenic INSR alleles is currently being developed for access by the community both to accelerate confident molecular diagnosis of newly identified rare INSR variants, and also to aid stratification of mutations according to potential for activation by non canonical INSR ligands. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555934/ http://dx.doi.org/10.1210/jendso/bvad114.893 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes And Glucose Metabolism
Aslanzadeh, Vahid
Brierley, Gemma
Kudla, Grzegorz
Kenneth Semple, Robert
OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title_full OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title_fullStr OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title_full_unstemmed OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title_short OR18-01 Massively Parallel Functional Assay Of Extracellular Insulin Receptor Variants
title_sort or18-01 massively parallel functional assay of extracellular insulin receptor variants
topic Diabetes And Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555934/
http://dx.doi.org/10.1210/jendso/bvad114.893
work_keys_str_mv AT aslanzadehvahid or1801massivelyparallelfunctionalassayofextracellularinsulinreceptorvariants
AT brierleygemma or1801massivelyparallelfunctionalassayofextracellularinsulinreceptorvariants
AT kudlagrzegorz or1801massivelyparallelfunctionalassayofextracellularinsulinreceptorvariants
AT kennethsemplerobert or1801massivelyparallelfunctionalassayofextracellularinsulinreceptorvariants